A multi-omics study integrating single-cell transcriptomics, spatial transcriptomics, and mendelian randomization unveil the implication of TRDMT1 expression in T cells on the immunotherapeutic response and prognosis in breast cancer
Mendelian randomization analysis indicated that the expression of the m5C writer tRNA aspartate methyltransferase 1 (TRDMT1) in blood was associated with breast cancer prognosis, and the immunotherapy predict value and prognostic value of measuring TRDMT1 levels in CD8+ T cells were confirmed.